Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25192823 | 0.95 | SMN1; SMN2 (0.45) | HPGDSIGMAR1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL25173709 | 0.80 | USP30 (0.48) | KMT2ASMN1; SMN2MEN1LMNAMAPK1 | |
| SCHEMBL10186558 | 0.77 | SMN1; SMN2 (0.51) | HPGDKMT2ASMN1; SMN2MEN1LMNA | |
| Benzene SCHEMBL29155321 | 0.76 | USP2 (0.53) | HPGDSIGMAR1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL29155320 | 0.74 | SIGMAR1 (0.45) | SIGMAR1KMT2AMAPK1KDM4EPOLB | |
| SCHEMBL7875487 | 0.74 | ALDH1A1 (0.45) | SMN1; SMN2LMNAALDH1A1USP30GPR119 | |
| SCHEMBL12551255 | 0.73 | FAAH (0.43) | SMN1; SMN2LMNAMAPK1ALDH1A1KDM4E | |
| Biphenyl SCHEMBL27296417 | 0.73 | SIGMAR1 (0.58) | HPGDSIGMAR1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4070722 | 0.73 | CYP2C9 (0.48) | KMT2ASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL4681390 | 0.72 | MEN1 (0.56) | SIGMAR1KMT2ASMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250018051-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-01-16 | — | — | US | disclosed |
| EP-4429707-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | Nerviano Medical Sciences S.r.l. (IT) | 2024-09-18 | — | — | EP | disclosed |
| CN-118215506-A | Anthracycline derivative linker reagent, antibody-drug conjugate and method | 内尔维亚诺医疗科学公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023083716-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180061-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | Nerviano Medical Sciences S.r.l. (IT) | 2023-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018051-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | DCTD, BCR, DUT | HPGD 1725/4885SIGMAR1 4701/4885KMT2A 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.